Oncolytics Biotech Says FDA Grants Fast Track Designation To Pelareorep In Combination With Bevacizumab And Leucovorin, FOLFIRI For Treatment Of Patients With KRAS-Mutant, MSS mCRC In 2L Setting

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population

Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of 2026

Pelareorep now has Fast Track Designation for two gastrointestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastrointestinal cancers

SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin®) and leucovorin, fluorouracil, irinotecan ("FOLFIRI") for the treatment of patients with KRAS ("Kirsten rat sarcoma")-mutant, microsatellite-stable ("MSS") metastatic colorectal cancer ("mCRC") in the second-line ("2L") setting. As part of the Company's increased focus on gastrointestinal cancer and analysis of the existing colorectal data set in the fall, the Company applied for and has now received Fast Track Designation.

The Fast Track Designation is supported by clinical data demonstrating a 33% objective response rate ("ORR") for pelareorep-based therapy compared to approximately 10% ORR with standard-of-care ("SOC") in this patient population.1-2 In addition, pelareorep combination therapy was associated with a median progression-free survival ("PFS") of 16.6 months, compared to 5.7 months with SOC, and a median overall survival ("OS") of 27 months, compared to 11.2 months with SOC.